Addressing a Major Gap in the
Treatment of Dry Eye Disease


Tuesday, October 3
8:00 - 9:00 PM ET

5:00 - 6:00 PM PT



Damon Dierker, OD, FAAO
Eye Surgeons of Indiana

Jennifer Loh, MD
Loh Ophthalmology Associates

Thursday, October 5
7:00 - 8:00 PM ET

4:00 - 5:00 PM PT



Mile Brujic, OD 
Owner of Premier Vision Group 

Sheri Rowen, MD
Newport Beach LASIK

Thursday, October 19
7:00 - 8:00 PM ET

4:00 - 5:00 PM PT



Nora Lee Cothran, OD, FAAO 
The Eye Institute of West Florida

Jay Pepose, MD 
Professor of Clinical ophthalmology and visual sciences at Washington University School of Medicine

Wednesday, November 1
9:00 - 10:00 PM ET
6:00 - 7:00 PM PT



Derek Cunningham, OD, FAAO
Dell Laser Consultants 

Crystal Brimer, OD, FAAO
Owner of Dry Eye Equation


Tuesday, November 14
8:00 - 9:00 PM ET
5:00 - 6:00 PM PT



Jade Coats, OD
McDonald Eye Associates

Melissa Toyos, MD
Partner in Toyos Clinic


Wednesday, November 29
8:00 - 9:00 PM ET
5:00 - 6:00 PM PT



Melissa Barnett, OD
Davis Medical Center

John D. Sheppard, MD
President of Virginia Eye Consultants


Thursday, December 14
10:00 - 11:00 PM ET

7:00 - 8:00 PM PT



April Jasper, OD
Advanced Eyecare Specialists

Mitch Ibach, OD, FAAO
Cornea, Cataract, Refractive, & Glaucoma Surgery Specialist


MIEBO™ (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for the treatment of the signs and symptoms of dry eye disease.


  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • The most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Click here for full Prescribing Information for MIEBO.

Reference: 1. MIEBO Prescribing Information. Bausch & Lomb Incorporated.

Sponsored by


©2023 Bausch & Lomb Incorporated or its affiliates. All rights reserved.  MBO.0169.USA.23
All Information pertains to the U.S. only, unless otherwise indicated.

Brought to you by